Back

Efficacy and safety of Alirocumab once-monthly dosing in patients with atherosclerotic cardiovascular disease and without acute coronary syndrome or stroke; an ODYSSEY CHOICE I analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Drug therapy (2) Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Clara Bonanad Lozano

Research Foundation Hospital of Valencia (INCLIVA), Valencia (Spain)

6 More presentations in this session

Presentation thumbnail
Bempedoic acid in clinical practice.
Doctor J. Vazquez Reguera (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Association of lipid-lowering drug treatment with all-cause and cardiovascular mortality among people aged 75 years and above without cardiovascular disease: evidence from a cohort study
Assistant Professor Z. Yang (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
LDL on target - strike early and strike strong... just strike...
Doctor L. Hamann (Faro, PT)
Abstract Slides Video
Presentation thumbnail
VICTORION IMPLEMENT: an observational study of the lipid management landscape in Germany
Professor O. Weingaertner (Jena, DE)
Abstract Slides Video
Presentation thumbnail
Analytical approaches to open label extension (OLE) after cardiovascular outocmes trials: Observations from the FOURIER and FOURIER-OLE trials
Doctor H. Wang (Newbury Park, US)
Abstract Slides Video

Access the full session

Session thumbnail
Drug therapy (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events
thumbnail
Congress Presentation
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease
thumbnail
Congress Presentation
What’s new on lipid-lowering drugs: from statins to gene editing and beyond

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources